Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd. - Common Shares (NQ: CYTO )

0.3001 UNCHANGED
Streaming Delayed Price Updated: 3:55 PM EST, Dec 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Altamira Therapeutics Ltd. - Common Shares

< Previous 1 2 3 4 Next >
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Provides Update on Nasdaq Listing
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Provides Business Update
From Altamira Therapeutics Ltd
Via GlobeNewswire
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
From FN Media Group LLC
Via GlobeNewswire
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Provides Investor and Business Update
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
From Altamira Therapeutics Ltd
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.